Theralase Technologies Inc. (CVE:TLT – Get Free Report)’s share price traded down 20% on Tuesday . The company traded as low as C$0.19 and last traded at C$0.19. 1,001,827 shares traded hands during trading, an increase of 332% from the average session volume of 231,764 shares. The stock had previously closed at C$0.24.
Theralase Technologies Trading Down 20.8%
The company has a market capitalization of C$56.18 million, a price-to-earnings ratio of -13.57 and a beta of -0.57. The company has a 50-day moving average price of C$0.25 and a 200-day moving average price of C$0.27. The company has a quick ratio of 3.40, a current ratio of 1.37 and a debt-to-equity ratio of 22.13.
About Theralase Technologies
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Recommended Stories
- Five stocks we like better than Theralase Technologies
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
